Teva Shares Encouraging Patient Survey Data For Long-Acting Olanzapine
The Survey Shows A Preference For The Formulation Among Patients And Professionals
Doubling down on previously shared data from the firm’s STELARIS trial, Teva has reported further findings from a survey featuring subjects and professionals involved in the Phase III study for its proposed long-acting olanzapine injectable.
